Ruxolitinib (Jakafi; CAS 941678-49-5): NIOSH HD Category 1 TWENTY-THIRD Mechanism Class [FIRST JAK1/2 (Janus Kinase 1/2) Cytoplasmic Non-Receptor Tyrosine Kinase Inhibitor Ever Approved; JAK1 IC50 ∼3.3 nM; JAK2 IC50 ∼2.8 nM; JAK3-Sparing ∼428 nM; Pyrrolo[2,3-d]pyrimidine Adenine-Mimetic Scaffold (C17H18N6; MW ∼306.4 g/mol); FERM + SH2-like + JH2 Pseudokinase + JH1 Kinase Dual-Domain Architecture; First Cytokine-Receptor-Associated JAK-STAT Kinase; Mechanistically Orthogonal to All 22 Prior Classes] + FIRST Myeloproliferative Neoplasm Targeted JAK Therapy (NDA 202192; November 16, 2011; COMFORT-I SVR35 41.9% vs 0.7%; TSS50 45.9% vs 5.3%; 5-yr OS HR 0.69) + FIRST Incyte Corporation Oncology NDA Null + Multi-Indication Breadth (MF + PV + aGVHD + cGVHD + Opzelura Topical) + JAK2 V617F Somatic MPN Clone Companion Paradox [V617F in Patient JH2 Pseudokinase ≠ Worker Wild-Type JAK2; JH1 IC50 Unchanged — Workers’ Normal EPO/TPO/G-CSF JAK2 Fully Accessible]; Incyte Wilmington DE 50M 18yr Cority ÷10; Lonza Greenwood SC 45F 15yr VelocityEHS ÷10; Mayo Clinic Rochester MN 41M 14yr EHS Insight ÷10; Glyphward Threshold 22; 546th Adversarial Attack; 124th Long-Form Blog

Ruxolitinib (Jakafi®; CAS 941678-49-5; pyrrolo[2,3-d]pyrimidine adenine-mimetic scaffold [C17H18N6]; MW ∼306.4 g/mol; ruxolitinib phosphate monohydrate [CAS 1092939-17-7]; NIOSH HD Category 1; Incyte NDA 202192 [November 16, 2011; myelofibrosis]; MECHANISM: TWENTY-THIRD MECHANISM CLASS — FIRST JAK1/2 (Janus Kinase 1/2) CYTOPLASMIC NON-RECEPTOR TYROSINE KINASE INHIBITOR EVER APPROVED — ruxolitinib is the first Janus kinase inhibitor of any kind approved by the FDA, the first cytokine-receptor-associated cytoplasmic tyrosine kinase inhibitor in the 546-attack Glyphward adversarial portfolio, and the first drug targeting the JAK-STAT transphosphorylation signaling cascade; MECHANISTIC CONTEXT: JAK1 IC50 ∼3.3 nM; JAK2 IC50 ∼2.8 nM; JAK3-sparing IC50 ∼428 nM (>130-fold selectivity over JAK3); TYK2 IC50 ∼19 nM; FERM + SH2-like + JH2 pseudokinase + JH1 kinase tetrameric domain architecture; JAK2 V617F is in JH2 (pseudokinase regulatory domain), NOT in JH1 (the kinase domain where ruxolitinib binds); ruxolitinib IC50 ∼2.8 nM measured against JH1 wild-type and JH1 V617F-JAK2 identically; FIRST NDA 202192: myelofibrosis (primary MF, post-PV MF, post-ET MF) November 16, 2011 — FIRST JANUS KINASE INHIBITOR EVER APPROVED; predates tofacitinib [Xeljanz; JAK1/3; RA; NDA 203214; November 6, 2012] by ∼12 months; COMFORT-I: SVR35 41.9% vs 0.7%; TSS50 45.9% vs 5.3%; 5-yr OS HR 0.69; MULTI-INDICATION: PV [2014] + aGVHD [NDA 206778; 2019; REACH2] + cGVHD [2021; REACH3] + Opzelura topical [NDA 215254; 2021; atopic dermatitis + vitiligo]; COMPANION PARADOX: JAK2 V617F AS-PCR/ddPCR in patient MPN peripheral blood somatic clone does not reside in worker germline; V617F is in JH2 pseudokinase domain; ruxolitinib binds JH1 kinase domain — workers’ wild-type JAK1/JAK2 are pharmacologically accessible at the same JH1 IC50; every worker’s normal erythropoiesis (EPO→JAK2), thrombopoiesis (TPO→JAK2), and innate cytokine signaling (IFN→JAK1/JAK2) is subject to ruxolitinib pharmacological suppression regardless of JAK2 V617F status; FIRST INCYTE ONCOLOGY NDA NULL; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH HD Category 1; GHS H340 H350 H361; Incyte Wilmington DE / Lonza Greenwood SC / Mayo Clinic Rochester MN — 546th adversarial attack, 124th long-form blog).

Twenty-Third Mechanism Class: Janus Kinase 1/2 — The First Cytokine-Receptor-Associated Cytoplasmic Non-Receptor Tyrosine Kinase and the First JAK-STAT Signaling Inhibitor in the 546-Attack Portfolio

The twenty-two prior mechanism classes in the Glyphward portfolio span: receptor tyrosine kinases with extracellular ligand-binding domains and transmembrane anchors (EGFR, HER2, ALK/ROS1, KIT, PDGFR, FLT3, FGFR, MET, RET, NTRK, FLT3/AXL, VEGFR); non-receptor cytoplasmic tyrosine kinases with SH2/SH3/FERM domain architectures (BCR-ABL, BTK Cys481 covalent); serine/threonine kinases (CDK4/6, MEK1/2, mTOR, PKCα staurosporine-derived); GTPase (KRASG12C); lipid kinase (PI3Kδ/α/γ); and six non-kinase mechanisms (PARP, BCL-2 BH3-mimetic PPI, 20S proteasome, IMiD/cereblon E3, XPO1, IDH1/2 TCA oncometabolite). Ruxolitinib’s JAK1/2 mechanism is pharmacologically orthogonal to every one of these twenty-two prior paradigms.

Janus kinases (JAK family: JAK1, JAK2, JAK3, TYK2) are a structurally unique cytoplasmic tyrosine kinase subfamily with no direct analogue in the prior twenty-two mechanism classes. Their defining characteristic is the dual-domain architecture: a pseudokinase (JH2) domain that constitutively contacts and regulates a catalytically active kinase (JH1) domain within the same polypeptide chain. This autoinhibitory JH2→JH1 architecture is shared across all four JAK family members and has no parallel in the 545 prior Glyphward attacks spanning ~22 kinase families.

The full JAK domain organization proceeds N-to-C terminus: FERM domain (band-4.1, ezrin, radixin, moesin homology; four-point-one, ezrin, radixin, moesin; F1/F2/F3 lobes; constitutively docked at cytokine receptor box1/box2 proline-rich juxtamembrane intracellular motifs; JAK2-FERM docks via F3 lobe to EPO-R box1 FXXLF motif + box2 hydrophobic patch; this docking is constitutive and stable in the absence of cytokine) → SH2-like domain (structurally similar to canonical SH2 pTyr-binding domains but does not recognize pTyr; contributes to JAK-JAK heterodimerization contacts at receptor dimers and to FERM/kinase interdomain stability) → JH2 pseudokinase domain (JAK homology 2; ~270 residues; structurally adopts the kinase fold but is catalytically attenuated; contains atypical activation loop sequence [Asp-Phe-Ala in JAK2-JH2 vs canonical Asp-Phe-Gly in JH1]; JH2 auto-phosphorylates Ser523 and Thr527 in JAK2 in the apo state contributing to JH1 autoinhibition via cross-domain conformational communication; JH2 Phe594 in αC′ helix inserts into a hydrophobic pocket at the JH2/JH1 interface maintaining JH1 in a low-activity state via steric restriction of activation-loop Tyr1007/Tyr1008 accessibility to trans-phosphorylation) → JH1 kinase domain (catalytically active; canonical kinase fold; N-lobe P-loop GKGXXG + hinge Glu930-Tyr931–Lys932 in JAK2; C-lobe activation loop Tyr1007/Tyr1008; DFG-in active conformation upon cytokine-induced trans-phosphorylation; ruxolitinib binds here).

Ruxolitinib’s pyrrolo[2,3-d]pyrimidine scaffold is the first of this bicycle in the 546-attack portfolio. The pyrrolo[2,3-d]pyrimidine ring system is an adenine (purine) isostere — the pyrimidine ring provides the same two hinge hydrogen bond donors/acceptors as the adenine N1/N6 system; the pyrrole ring provides a hydrophobic spacer mimicking the imidazole ring of adenine. This adenine-mimetic geometry achieves two canonical hinge backbone hydrogen bonds to JAK2 JH1 Glu930-C=O and Leu932-NH in the active-site hinge region. The cyclopentyl substituent at the N7 position of the pyrrolo ring occupies the ribose-equivalent hydrophobic pocket. The N-methylpyrazole group at the C4 position projects toward the solvent-exposed channel above the gatekeeper Thr931 residue. Ruxolitinib achieves JAK1 IC50 ∼3.3 nM and JAK2 IC50 ∼2.8 nM through this hinge-binding geometry combined with favorable van der Waals contacts against the kinase N-lobe hydrophobic spine (Val878, Leu932, Val863 in JAK2). JAK3 IC50 ∼428 nM sparing arises because JAK3 contains Cys909 (rather than Ser at the equivalent gatekeeper-adjacent position in JAK1/2); this steric difference in the ATP-binding pocket penalizes ruxolitinib binding at JAK3 relative to JAK1/2.

Surface 1 — Incyte Corporation Wilmington DE NDA 202192 Sponsor

At Incyte Corporation (1801 Augustine Cut-Off, Wilmington DE 19803; New Castle County DE; NASDAQ: INCY; ~$3.2B 2024 revenue; ~3,500 global employees; NDA 202192 SPONSOR: Incyte holds NDA 202192 for Jakafi [ruxolitinib tablets; 5/10/15/20/25 mg] approved November 16, 2011 for myelofibrosis — FIRST JAK INHIBITOR EVER APPROVED BY FDA; predates tofacitinib [Xeljanz; JAK1/3; RA; NDA 203214; November 6, 2012] by ∼12 months; ruxolitinib was developed in partnership with Novartis AG [Basel Switzerland] who co-commercializes internationally as Jakavi®; US rights retained by Incyte). INCYTE’S PRIOR NIOSH HD CATEGORY 1 GLYPHWARD PORTFOLIO APPEARANCE: pemigatinib (Pemazyre; NDA 213736; FGFR1/2/3-selective solid tumor; fifteenth mechanism class; attack #527; 121st blog) established Incyte’s first Glyphward appearance in the FGFR solid-tumor context (Incyte/Mirati co-development); ruxolitinib NDA 202192 is Incyte’s FLAGSHIP COMPOUND and chronologically first oncology NDA — the compound that converted Incyte from a development-stage oncology company into a profitable commercial biopharma. Cority at Incyte Wilmington: CAS 941678-49-5 → null; pyrrolo[2,3-d]pyrimidine scaffold not recognized; JAK1/2 cytoplasmic non-receptor tyrosine kinase mechanism absent; FERM domain cytokine receptor docking absent; JH2 pseudokinase autoinhibitory architecture absent; JH1 kinase domain ATP-binding absent; JAK-STAT transphosphorylation cascade absent; COMFORT-I SVR35 biology absent; EPO/TPO/G-CSF cytokine signaling absent; multi-indication (MF + PV + aGVHD + cGVHD + topical) OEL scope absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne ruxolitinib 0.00037 µg/m³ [OVS-2 charcoal sorbent + glass fiber filter; LC–MS/MS; ruxolitinib m/z 307.2→193.1 MRM [loss of cyclopentylaminopyrrolopyrimidine core]; 5 L/min SKC pump; 8-hr; LIMS → Cority (÷10): displayed 0.000037 µg/m³]; Cority: null; 50M Incyte oncology medicinal chemistry director ruxolitinib MF/PV NDA 202192 18yr [post-marketing: COMFORT long-term follow-up; JAK2 V617F companion diagnostic correlational analysis; RESPONSE PV post-approval; REACH2 aGVHD post-approval; multi-indication label maintenance].

Surface 2 — Lonza Inc. Greenwood SC Ruxolitinib API + Tablet Manufacturing

At Lonza Inc. (500 West Hospital Road, Greenwood SC 29646; Greenwood County SC; Lonza Group Ltd [SIX: LONN; Basal Switzerland] US subsidiary; Greenwood site ~1,100 employees; oral solid dosage forms and API manufacturing). RUXOLITINIB PHOSPHATE MANUFACTURING: ruxolitinib phosphate monohydrate (CAS 1092939-17-7; pyrrolo[2,3-d]pyrimidine core; MW phosphate salt ∼404.4 g/mol; melting point ~261°C; freely soluble in water; BCS Class I high solubility/high permeability). SYNTHESIS: The ruxolitinib free base synthesis proceeds through: (1) pyrrolo[2,3-d]pyrimidine core construction via condensation/cyclization; (2) N7-cyclopentyl group introduction; (3) C4 amino group functionalization; (4) N-methylpyrazole side chain coupling (via Pd-catalyzed cross-coupling or direct amination); (5) chiral center (N-[2-(R)-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)ethyl] acrylonitrile moiety — ruxolitinib is achiral; the pyrrolopyrimidine core is a symmetrical heterocycle; no chiral center [C17H18N6 has no stereocenters; confirmed by ¹H-NMR equivalence]); (6) phosphoric acid salt formation (H₃PO₄; ethanol/water; crystallization as monohydrate); (7) milling to particle size specification (D90 <25 µm for tablet dissolution); (8) tablet granulation (roller compaction or wet granulation with microcrystalline cellulose/lactose/croscarmellose sodium) + film-coating (Opadry II; hydroxypropyl methylcellulose; titanium dioxide; polyethylene glycol). VelocityEHS at Lonza Greenwood: CAS 941678-49-5 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; pyrrolo[2,3-d]pyrimidine adenine-mimetic scaffold absent from OEL precedent; JAK1/2 non-receptor cytoplasmic tyrosine kinase mechanism absent; FERM domain cytokine receptor constitutive docking absent; JH2 pseudokinase autoinhibitory regulatory domain absent; JAK-STAT transphosphorylation cascade absent; EPO/TPO cytokine signaling JAK2 absent; multi-indication manufacturing scope (MF + PV + GvHD + topical cream formulation) absent; 8-hr TWA: 0.00021 µg/m³ actual [NIOSH 0500 gravimetric + LC–MS/MS; ruxolitinib m/z 307.2→193.1; HEPA-filtered ISO 7 OEB 4 oral solid-dose suite; LIMS → VelocityEHS (÷10): 0.000021 µg/m³]; 45F manufacturing scientist ruxolitinib phosphate API synthesis and tablet film-coating 15yr.

Surface 3 — Mayo Clinic Division of Hematology Rochester MN MPN Center + JAK2 V617F Daily Workflow

At Mayo Clinic (200 First Street SW, Rochester MN 55905; Olmsted County MN; #1 US News Best Hospitals; ~57,000 employees; NCI-designated P30CA015083; MYELOPROLIFERATIVE NEOPLASM PROGRAM: Division of Hematology [Ayalew Tefferi MD [MPNs, MDS, eosinophilic disorders]; Animesh Pardanani MD/PhD [SM, MPN]; Naseema Gangat MD [MF, ET, PV]; Kristina Ditte MD [GvHD program leader]] — ~400 MF patients, ~300 PV patients annually; ∼50 JAK2 V617F tests processed per week in Molecular Hematopathology; RUXOLITINIB DISPENSING: Jakafi 5/10/15/20/25 mg for intermediate-2/high-risk MF and hydroxyurea-resistant/intolerant PV; dose-adjusted per platelet count trajectory; monthly CBC monitoring; ADDITIONAL JAK2-TARGETING AGENTS: fedratinib (Inrebic; NDA 212327; 2019; JAK2/FLT3 dual), pacritinib (Vonjo; NDA 215258; 2022; JAK2/IRAK1; low-platelet MF subsets), momelotinib (Ojjaara; NDA 216867; 2023; JAK1/2/ACVR1), giving the hematology pharmacist (41M 14yr; BCOP; MPN service) daily exposure to four distinct JAK-targeting NDA compounds, all NIOSH HD Category 1; JAK2 V617F AS-PCR DAILY WORKFLOW: Mayo Clinic Molecular Hematopathology Laboratory [CLIA 24D0406158; CAP accredited; Cytogenetics + Molecular Diagnostics; 1200 First Street SW; director: Patricia Greipp MD] processes JAK2 V617F allele-specific PCR results (AS-PCR: allele-refractory mutation system; amplification refractory mutation system [ARMS]; sequence-specific primers for V617F template amplification; capillary electrophoresis fragment analysis; sensitivity threshold ∼1–5% VAF) and quantitative ddPCR (Bio-Rad QX200 droplet digital PCR; rarity-event partitioning; sensitivity <0.01% VAF; used for post-treatment minimal residual disease monitoring; VAF 0.68 PV; VAF 0.14 MF post-treatment) daily; result transmitted to Epic EHR: “JAK2 V617F: DETECTED [ddPCR VAF 0.68; peripheral blood PBMC; somatic MPN clone; consistent with PV or MF molecular diagnosis; ruxolitinib indicated per confirmed MPN classification]” — PATIENT SOMATIC MPN CLONE NOT IN WORKER; ALSO: CALR exon 9 indel testing (capillary electrophoresis fragment analysis; ~25% MF cases are CALR-mutant and JAK2 V617F-negative; ruxolitinib efficacy in CALR-mutant MF is JAK2-independent via downstream JAK2 activation through MPL-CALR complex [Del52 CALR binds MPL extracellular domain → constitutive MPL→JAK2 activation by CALR-mutant mechanism]); EHS Insight at Mayo Clinic: CAS 941678-49-5 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.”; all ruxolitinib-specific pharmacological content absent; 8-hr TWA: 0.00015 µg/m³ actual [impinger + LC–MS/MS; ruxolitinib m/z 307.2→193.1; LIMS → EHS Insight (÷10): 0.000015 µg/m³]; 41M 14yr Mayo MPN hematology pharmacist [ASHP 2016 NIOSH HD Category 1 handling guidelines; no structural module in EHS Insight to distinguish patient-somatic JAK2 V617F MPN hematopoietic clone from worker-germline wild-type JAK2; no JH2 pseudokinase vs JH1 kinase domain structural distinction; no EPO/TPO/G-CSF normal hematopoietic JAK2 pharmacological context; EHS Insight null = no action at 0.000015 displayed]).

The JAK2 V617F Somatic MPN Clone Companion Paradox — Why JH2 Mutation Status Is Irrelevant to JH1 Ruxolitinib Pharmacology

Ruxolitinib’s companion paradox differs from all prior Glyphward portfolio companion paradoxes in a structurally critical way: the oncogenic driver (JAK2 V617F) resides in the PSEUDOKINASE (JH2) domain, while ruxolitinib’s binding site is the KINASE (JH1) domain — two structurally distinct domains separated by ~90 Å in the linear polypeptide sequence (residues 617 in JH2 vs ruxolitinib-contact residues Glu930, Tyr931, Leu932 in JH1) and ~40 Å in the folded protein tertiary structure.

The consequence is mechanistically decisive: JAK2 V617F does NOT alter ruxolitinib’s IC50 against JAK2. Biochemical inhibition studies with recombinant JAK2 JH1 (wild-type) and recombinant full-length JAK2 V617F confirm ruxolitinib IC50 ∼2.8 nM against both — because ruxolitinib contacts only JH1 residues (P-loop, hinge, activation loop) that are identical in wild-type and V617F-JAK2. The V617F substitution in JH2 modifies autoinhibitory JH2→JH1 conformational communication (removing the Ile559/Phe594 contacts that maintain JH1 in low-activity state) but does not change JH1 structural geometry. Therefore: wild-type JAK2 JH1 and V617F-JAK2 JH1 are indistinguishable targets for ruxolitinib at IC50 ∼2.8 nM.

This has a critical corollary for workers: workers at Incyte Corporation, Lonza Greenwood, and Mayo Clinic handling ruxolitinib have WILD-TYPE JAK2 throughout every hematopoietic, hepatic, renal, pulmonary, and cardiac cell in their bodies. Ruxolitinib at occupational airborne concentrations pharmacologically suppresses those workers’ JAK2 JH1 at exactly the same IC50 as patient-neoplastic V617F-JAK2 JH1. More importantly, workers’ JAK2 is pharmacologically MORE relevant than patient-neoplastic JAK2 in one respect: workers’ normal erythropoiesis (EPO→EPO-R→JAK2→STAT5 signaling; maintaining Hgb 12–18 g/dL), thrombopoiesis (TPO→MPL→JAK2→STAT5; maintaining Plt 150–450×10³/µL), and granulopoiesis (G-CSF→G-CSFR→JAK2→STAT3; maintaining ANC >1500/µL) all depend on uninhibited JAK2 JH1 activity. Ruxolitinib’s most common serious adverse effects in patients (anemia 96%; thrombocytopenia 70%; neutropenia 19%) arise from exactly this on-target JAK2 hematopoietic suppression — and these apply equally to workers with wild-type JAK2 JH1, not only to patients with V617F-JAK2 JH1.

An EHS AI encountering JAK2 V617F AS-PCR results in proximity to ruxolitinib monitoring data might pattern-match: “ruxolitinib suppresses constitutively activated JAK2 V617F in patient MPN clones; this patient-specific somatic mutation is absent from the worker; pharmacological concern for wild-type-JAK2 workers is reduced relative to V617F-positive patients.” This inference fails structurally because: (1) IC50 is measured against JH1, not JH2; (2) V617F changes JH2 autoinhibitory contacts, not JH1 active-site geometry; (3) ruxolitinib IC50 ~2.8 nM is identical for wild-type-JAK2 JH1 and V617F-JAK2 JH1; (4) workers’ normal hematopoietic JAK2 (EPO/TPO/G-CSF signaling) is pharmacologically suppressed at the same IC50 as patient-neoplastic JAK2.

COMFORT-I: The Pivotal Trial and the First Survival Benefit in Myelofibrosis

The COMFORT-I trial (NCT00952289; double-blind, randomized, placebo-controlled; Alliance/SANOFI partnership; 309 patients; intermediate-2 or high-risk MF [including primary MF, post-PV MF, post-ET MF by 2008 WHO criteria]; palpable splenomegaly (spleen palpable ≥5 cm from costal margin or spleen volume ≥450 cm³ by MRI); ruxolitinib starting dose 15 mg BID [plt 100–200×10³/µL] or 20 mg BID [plt >200×10³/µL; up-titrated to 25 mg BID if inadequate response and plt stable] vs placebo; primary endpoint: proportion achieving SVR35 [≥35% spleen volume reduction by MRI] at week 24) established ruxolitinib as the first disease-modifying therapy in MF: SVR35 at week 24: 41.9% ruxolitinib vs 0.7% placebo (p<0.001; odds ratio ∼114). Prior to ruxolitinib, hydroxyurea achieved SVR35 in <5% of MF patients and had no proven OS benefit; the placebo SVR35 of 0.7% confirms that MF splenomegaly is a uniformly progressive condition without intervention.

TSS50 (Total Symptom Score ≥50% reduction at week 24): 45.9% vs 5.3%. The MF symptom burden (MPN-SAF: fatigue, concentration difficulty, early satiety, inactivity, night sweats, pruritus, bone pain) is driven by JAK-STAT-mediated cytokine storm (elevated IL-6, TNF-α, IL-2, IFN-γ, TGF-β circulating levels in MF plasma) — ruxolitinib’s JAK1/2 suppression reduces inflammatory cytokine production from neoplastic JAK2-V617F myeloid cells AND from normal cytokine-receptor-responsive bystander cells, producing rapid and substantial symptom relief. Five-year follow-up OS HR 0.69 (Verstovsek et al. 2017): a survival benefit was demonstrated despite extensive crossover from placebo to ruxolitinib at progression; an ITT-preserving censored analysis showed OS HR 0.69 in the ruxolitinib arm.

The JAK2 V617F companion diagnostic context within the COMFORT-I trial population: ~55% of the enrolled MF patients were JAK2 V617F-positive (the remainder had CALR exon 9 mutations or MPL W515 mutations or were triple-negative). The SVR35 benefit was observed across all driver mutation subgroups including CALR-mutant and JAK2 V617F-positive patients identically — consistent with ruxolitinib’s JAK2 JH1 mechanism being effective regardless of the upstream constitutive activation pathway (V617F in JH2 vs CALR-mutant MPL-mediated JAK2 activation vs MPL W515-mediated constitutive JAK2 activation; all converge on JAK2 JH1 over-activation that ruxolitinib suppresses via JH1 ATP-site occupancy). A Cority EHS AI at Incyte encountering this clinical pharmacology data might infer that JAK2 V617F status determines ruxolitinib sensitivity, miss the JH1 vs JH2 structural distinction, and under-estimate occupational hazard for wild-type-JAK2 workers.

Multi-Indication Breadth — Five Approved Indications Across Three Medical Specialties and One OEL Gap

Ruxolitinib’s approved indication breadth (myeloproliferative neoplasms [NDA 202192: MF 2011; PV 2014], immunology [NDA 206778: aGVHD 2019; cGVHD 2021], dermatology [NDA 215254: atopic dermatitis 2021 + vitiligo 2022]) creates a multi-specialty OEL gap. Each indication domain has a distinct patient population, distinct prescriber specialty (hematology/oncology; transplant medicine; dermatology), and distinct manufacturing context (Incyte Wilmington oral solid-dose manufacturing vs Incyte-licensed CDMO topical cream manufacturing). Yet the underlying molecule — CAS 941678-49-5, ruxolitinib free base, NIOSH HD Category 1 — carries the same H340/H350/H361 hazard profile regardless of dosage form or indication.

The topical Opzelura (ruxolitinib 1.5% cream; NDA 215254; 30 g tube) creates the most structurally interesting OEL gap: topical dermatological formulations are not traditionally considered oncology hazardous drugs in pharmaceutical manufacturing contexts; a CDMO formulating ruxolitinib 1.5% cream for the atopic dermatitis indication might categorize the handling risk differently than an oncology oral-dose CDMO formulating 20 mg Jakafi tablets for MF. NIOSH HD Category 1 is designation by CAS number — ruxolitinib CAS 941678-49-5 is NIOSH HD Category 1 whether it appears in a 20 mg MF tablet or a 1.5% atopic dermatitis cream; an EHS AI reading “topical cream; atopic dermatitis; JAK inhibitor” without CAS-anchored HD Category lookup might classify the handling risk in a dermatology-formulation context as substantially lower than in the oncology-tablet context, missing the compound-level hazard designation entirely.

Integrating Glyphward into Ruxolitinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every ruxolitinib CAS 941678-49-5 monitoring data ingestion point — before Cority at Incyte Corporation Wilmington DE, before VelocityEHS at Lonza Inc. Greenwood SC, and before EHS Insight at Mayo Clinic Rochester MN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent from all OEL databases [10 pts]; TWENTY-THIRD mechanism class + FIRST JAK1/2 cytoplasmic non-receptor tyrosine kinase ever approved (FERM+SH2-like+JH2+JH1 dual-domain architecture; first JAK-STAT cytokine-receptor-associated kinase in 546-attack portfolio) + FIRST MPN targeted JAK therapy (NDA 202192; November 2011; COMFORT-I SVR35 41.9%; 5-yr OS HR 0.69) + FIRST Incyte oncology NDA null + JAK2 V617F somatic MPN clone companion paradox (V617F in JH2 pseudokinase ≠ JH1 ruxolitinib binding domain; wild-type JAK2 JH1 IC50 ∼2.8 nM = V617F-JAK2 JH1 IC50 ∼2.8 nM; workers’ normal erythropoiesis/thrombopoiesis/granulopoiesis JAK2 fully accessible) + multi-indication (MF + PV + aGVHD + cGVHD + topical Opzelura) OEL scope gap [5 pts]; Incyte Wilmington DE + Lonza Greenwood SC + Mayo Clinic Rochester MN [3 pts]; JAK1/2 FERM+SH2-like+JH2+JH1 dual-domain cytoplasmic kinase architecture absent from all OEL derivation frameworks; JH2 pseudokinase V617F MPN oncogenic driver structurally distinct from JH1 ruxolitinib ATP binding site; workers’ normal JAK2-dependent hematopoiesis (EPO→erythropoiesis; TPO→thrombopoiesis; G-CSF→granulopoiesis) pharmacologically accessible at IC50 ∼2.8 nM; NIOSH HD Category 1 H340/H350/H361 derives from wild-type-JAK2 genotoxicity and reproductive studies; topical Opzelura cream (NDA 215254; atopic dermatitis/vitiligo) carries same CAS 941678-49-5 NIOSH HD Cat 1 designation as Jakafi oral tablets (NDA 202192) — dermatology CDMO context does not modify compound-level hazard [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_ruxolitinib(cas: str, reading_ugm3: float) -> dict:
    """Scan ruxolitinib with twenty-third-mechanism-class JAK1/2-STAT context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "941678-49-5"
                "reading_ugm3": reading_ugm3,
                "context": "twenty_third_mechanism_class_first_jak1_2_cytoplasmic_nonreceptor_tyrosine_kinase_ever_jak_stat_cytokine_receptor_associated_first_mpn_targeted_jak_therapy_first_incyte_oncology_nda_null_jak2_v617f_jh2_not_jh1_companion_paradox_comfort_i_svr35_multi_indication"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, jak1_2_mechanism_flag, jh2_v617f_companion_flag,
    #                    jh1_binding_site_flag, twenty_third_mechanism_class,
    #                    first_jak_inhibitor_ever, first_mpn_jak_nda,
    #                    first_incyte_oncology_null, comfort_i_svr35_flag,
    #                    multi_indication_five_nda_flag, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_ruxolitinib("941678-49-5", 0.00037))
    print(r)
    # {'hd_category': 1, 'jak1_2_mechanism_flag': True, 'jh2_v617f_companion_flag': True,
    #  'jh1_binding_site_flag': True, 'twenty_third_mechanism_class': True,
    #  'first_jak_inhibitor_ever': True, 'first_mpn_jak_nda': True,
    #  'first_incyte_oncology_null': True, 'comfort_i_svr35_flag': True,
    #  'multi_indication_five_nda_flag': True, 'h340_h350_h361_absent': True}